Esperion Therapeutics Inc (ESPR)

Currency in USD
2.760
+0.140(+5.34%)
Closed·
2.777+0.017(+0.63%)
·
ESPR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.6602.860
52 wk Range
0.6934.175
Key Statistics
Prev. Close
2.76
Open
2.67
Day's Range
2.66-2.86
52 wk Range
0.693-4.175
Volume
4.59M
Average Volume (3m)
4.86M
1-Year Change
69.3252%
Book Value / Share
-1.28
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ESPR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.991
Upside
+153.31%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Esperion Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Employees
294

Esperion Therapeutics Inc Earnings Call Summary for Q4/2025

  • Q4 revenue surged 144% YoY to $168.45M, driven by $124.7M collaboration revenue including Otsuka milestone payment.
  • EPS of $0.22 missed forecast of $0.29 by 24%, though stock rose 7.24% in pre-market to $3.26 on revenue strength.
  • US net product revenue grew 38% to $43.7M; company ended year with strong cash position and reduced debt levels.
  • CEO Mayleben cited 2025 as best year on record; projects 2026 operating expenses of $225M-$255M including $15M stock compensation.
  • Growth strategy focuses on new product launches and international expansion through strategic partnerships to sustain momentum.
Last Updated: 10/03/2026, 12:56
Read Full Transcript

Compare ESPR to Peers and Sector

Metrics to compare
ESPR
Peers
Sector
Relationship
P/E Ratio
−31.2x2.3x−0.5x
PEG Ratio
−0.520.840.00
Price/Book
−2.3x1.6x2.6x
Price / LTM Sales
1.8x1.9x3.1x
Upside (Analyst Target)
86.3%65.0%55.9%
Fair Value Upside
Unlock33.2%7.4%Unlock

Analyst Ratings

4 Buy
1 Hold
1 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 6.991
(+153.31% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BofA Securities
Sell1.78-35.51%-Maintain16/03/2026
Citizens
Buy5.00+81.16%4.00Maintain13/03/2026
H.C. Wainwright
Buy16.00+479.71%-Maintain10/03/2026
Piper Sandler
Buy9.00+226.09%-New Coverage25/11/2025
Cantor Fitzgerald
Buy90.00+3,160.87%-Maintain12/11/2025

Earnings

Latest Release
10/03/2026
EPS / Forecast
0.22 / 0.29
Revenue / Forecast
168.45M / 168.28M
EPS Revisions
Last 90 days

People Also Watch

4.530
ABUS
+5.10%
1.840
CERS
+3.95%
9.60
RLAY
+1.69%
1.560
IVVD
+9.09%
1.750
CDXS
+4.79%

FAQ

What Is the Esperion (ESPR) Share Price Today?

The Esperion stock price today is 2.760 USD.

What Stock Exchange Does Esperion (ESPR) Trade On?

Esperion is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Esperion?

The stock symbol (also called a 'ticker') for Esperion is "ESPR."

What Is the Current Esperion Market Cap?

As of today, Esperion market cap is 708.800M USD.

What Is Esperion's (ESPR) Earnings Per Share (TTM)?

The Esperion EPS is currently -0.109 (Trailing Twelve Months).

When Is the Next Esperion Earnings Date?

Esperion's next earnings report will be released on 12/05/2026.

Is ESPR a Buy or Sell From a Technical Analyst Perspective?

Based on today's Esperion moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Esperion Stock Split?

Esperion has split 0 times. (See the ESPR stock split history page for full effective split date and price information.)

How Many Employees Does Esperion Have?

Esperion has 294 employees.

What is the current trading status of Esperion (ESPR)?

As of 26/03/2026, Esperion (ESPR) is trading at a price of 2.760 USD, with a previous close of 2.760 USD. The stock has fluctuated within a day range of 2.660 USD to 2.860 USD, while its 52-week range spans from 0.693 USD to 4.175 USD.

What Is Esperion (ESPR) Price Target According to Analysts?

The average 12-month price target for Esperion is 6.991 USD, with a high estimate of 16 USD and a low estimate of 1.77998 USD. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +153.31% Upside potential.

What Is the ESPR After Hours Price?

ESPR's last after hours stock price is 2.777 USD, the stock has decreased by 0.017, or 0.630%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.